ArticleClinical ophthalmology (Auckland, N.Z.)2009
Age-related macular degeneration: current treatments.
Article in Clinical ophthalmology (Auckland, N.Z.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2011Trial
- Deep Learning-Enhanced Robotic Subretinal Injection with Real-Time Retinal Motion Compensation.IEEE International Conference on Automation Science and Engineering (CASE) : [proceedings]. IEEE Conference on Automation Science and Engineering · 2025Article
- Oculomotor challenges in macular degeneration impact motion extrapolation.Journal of vision · 2025Article
- Assessing REALTER simulator: analysis of ocular movements in simulated low-vision conditions with extended reality technology.Frontiers in bioengineering and biotechnology · 2024Article
- Enhanced Biosafety of theBiomolecules · 2023Article
- Mapping residual stereopsis in macular degeneration.Journal of vision · 2022Article
- Eye Movements in Macular Degeneration.Annual review of vision science · 2021Review
- Experimental Models in Neovascular Age Related Macular Degeneration.International journal of molecular sciences · 2020Review
- Use of Fundus Autofluorescence Combined with Optical Coherence Tomography for Diagnose of Geographic Atrophy in Age-Related Macular Degeneration.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Article
- Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges.NPJ Regenerative medicine · 2017Review
- Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Anxiety and depression in patients with advanced macular degeneration: current perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2016Review
- Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.Journal of medicinal chemistry · 2015Article
- Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies.PloS one · 2015Article
- Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.Journal of medicinal chemistry · 2014Article
- Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering.Journal of ophthalmology · 2014Review
- Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to Age-Related Macular Degeneration: A Review.Journal of ophthalmology · 2013Article
- Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough important progress has been made in understanding age-related macular degeneration (AMD), management of the disease continues to be a challenge. AMD research has led to a widening of available treatment options and improved prognostic perspectives. This essay reviews these treatment options.
designInterpretative essay.
methodsLiterature review and interpretation.
resultsCurrent treatments to preserve vision in patients with non-exudative AMD include antioxidant vitamins and mineral supplementations. Exudative AMD is currently most often treated monthly with anti-VEGF intravitreal injections. However, investigators are beginning to experiment with combination therapy and surgical approaches in an attempt to limit the number of treatment and reduce the financial burden on the health care system.
conclusionBy better understanding the basis and pathogenesis of AMD, newer therapies will continue to be developed that target specific pathways in patients with AMD, with the hoped for outcome of better management of the disease and improved visual acuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.